- Opinion
- [Reporter’s View] Asthma drugs await reimb discussions
- by Eo, Yun-Ho Feb 14, 2023 05:48am
- The asthma drugs that had long remained unreimbursed since their approval has resurfaced at the table for discussions, but the situation has not improved much from before. The government and the companies are seemingly unable to reach a consensus on the appropriate drug price. Three asthma biological drugs that were developed at similar
- Opinion
- [Reporter’s View] Improving NHI-related legislation
- by Lee, Jeong-Hwan Feb 6, 2023 05:51am
- The bill to remove the administrative drug price cut and reimbursement suspension dispositions that were imposed on illegal drug rebates from the current National Health Insurance Act and raising the penalty surcharge system has drawn industry attention and rose as an issue of focus this year. The bill aims to minimize third-party damage
- Opinion
- [Reporter's view] Leader's responsibility
- by Feb 3, 2023 05:53am
- One of the common grievances faced by employees of Korean subsidiaries of foreign companies is "Leader's irresponsibility." The representative of a Korean corporation is the head of a company in Korea, but he is one of the branch managers of many countries in the global view. Whether you like it or not, you have to follow the instructions of
- Opinion
- [Reporter’s View] CDDC continues to raise controversy
- by Eo, Yun-Ho Feb 1, 2023 05:54am
- The Cancer Disease Deliberation Committee has settled as the highest threshold in reimbursement for anticancer drugs in Korea. This expert committee, which is a mandatory step for reimbursement in Korea, has put many anticancer drugs through an ordeal, to the extent that it was coined the ‘wailing wall’ to reimbursement in Korea. The co
- Opinion
- [Reporter's view] There's no instability in supply & demand
- by Lee, Tak-Sun Jan 26, 2023 06:06am
- Last-minute discussions between the NHIS and the pharmaceutical industry are underway regarding PVA of cold medicines, which increased their use due to COVID-19 last year. The consultation began when the government decided to correct the usage instead when the pharmaceutical industry suggested that cold medicines, which have increased their
- Opinion
- [Reporter’s View] Our expectations for ADC technology
- by Jan 18, 2023 06:04am
- Professor Park Yeon-hee of the Hematology and Oncology department at Samsung Medical Center who recently spoke at the press conference held to celebrate the launch of ‘Enhertu’ in Korea said, “I have never seen such data in breast cancer.” This goes to show the superior efficacy of Enhertu in breast cancer. She added, “During the Enhert
- Opinion
- [Reporter's view] The Pharmaceutical Bio-Innovation Committe
- by Kim, Jin-Gu Jan 13, 2023 06:01am
- President Yoon Suk Yeol is in his second year in office. President Yoon made various pledges to foster the pharmaceutical bio-industry when he was a candidate. The first of them was to set up a pharmaceutical bio-innovation committee. The pharmaceutical bio-industry was excited by his pledge. Expectations were high for the organization in cha
- Opinion
- [Reporter’s View] Can new drug listings really be accelerat
- by Eo, Yun-Ho Jan 11, 2023 05:59am
- The measures to accelerate reimbursement listing of new drugs is expected to be implemented in earnest this year. However, the practicality of the measure &8211; on whether it will really accelerate drug listings &8211; remains in question. The health authorities made a preannouncement on the amendment of the pharmacoeconomic evaluation
- Opinion
- [Reporter’s View] Decide whether to reimb diabetes combos
- by Lee, Tak-Sun Jan 9, 2023 06:11am
- Once again, discussions on expanding reimbursement to combination therapies to treat diabetes are at a standstill. The Ministry of Health and Welfare was unimpressed with the price reduction plans submitted by relevant companies under the assumption that reimbursements are expanded. This discussion, which had shown small progress only rec
- Opinion
- [Reporter's view] Expectations for Revlimid
- by Eo, Yun-Ho Jan 3, 2023 05:41am
- The maintenance therapy of Revlimid, a treatment for multiple myeloma, has been on the insurance benefit list since the new year of 2023 after more than four years of waiting. Revlimid maintenance therapy has simply had a lot of ups and downs. Since 2019, BMS Pharmaceutical Korea has actively carried out the registration process, but there ha
